Skip to content

Bliss DTx Assessment During Course Care Including Port-A-Catheter Setting

Bliss DTx Assessment During Course Care Including Port-A-Catheter Setting

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06495528
Acronym
EPATPAC
Enrollment
318
Registered
2024-07-10
Start date
2024-06-12
Completion date
2025-05-12
Last updated
2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Setting a Port-a Cath is performed in a surgical room, under ambulatory, by a specialist, under local anesthesia. This Port-a Cath is placed in the upper part of the thorax, under the clavicle, and facilitate the administration of certain anticancer drugs or to inject other treatments throughout the course of care. Setting a Port-a Cath is painful and stressful. In addition to local anesthesia, patients are often offered a sedation: anxiolytics, hypnotics or inhalation of MEOPA. Butterfly Therapeutics has developed a Digital Therapeutics (DTx) called Bliss DTx which uses virtual reality augmented by sound and visual stimuli. A first clinical study with Bliss DTx showed that the pain level was not significantly different between Bliss DTx arm and MEOPA arm when performing osteomedullary biopsy. This study is based on the hypothesis that Bliss DTx use would : * Be clinically equivalent to a standard protocol (use of hypnotics and/or anxiolytics and/or MEOPA and/or hypnosis conversational) to manage pain during Port-a Cath setting under local anesthesia * Reduce anxiety before setting a Port-a Cath * Provide greater satisfaction with the treatment process from patient point of view * Have organizational impacts, some of which could be economically valued

Detailed description

An implantable catheter port, also called Port-a Cath, is placed in the upper part of the thorax under the clavicle. Setting is performed in a surgical room, under ambulatory, by a specialist, under local anesthesia. This Port-a Cath is set up to facilitate the administration of certain anticancer drugs or to inject other treatments throughout the course of care. Setting a Port-a Cath is painful and stressful. In addition to local anesthesia, patients are often offered a sedation: anxiolytics as premedication, hypnotics before or during the Port-a Cath setting, inhalation of MEOPA (equimolar mixture of oxygen and nitrogen protoxide, medicinal anxiolytic and analgesic gas , colorless and slightly odorous, mainly used in a hospital environment). Virtual reality technology allows a person to be immersed in a virtual environment using a device consisting of headset audio and 3D display system. This is a non-invasive device that has an effect on the anxiety and pain level of patients. Butterfly Therapeutics has developed a Digital Therapeutics (DTx) called Bliss DTx which uses virtual reality augmented by sound and visual stimuli. A first clinical study with Bliss DTx which was released in 2021 showed that the pain level was not significantly different between Bliss DTx arm and MEOPA arm when performing osteomedullary biopsy. Bliss DTx is also used in everyday practice by many doctors, surgeons, anesthetists and nurses, who do not observe significant pain difference between Bliss DTx and chemical sedations during the acts, but note interesting differences from an organizational point of view between the different methods. A new evolution of Bliss DTx offers features that allow to increase winnings throughout the course including installation of a Port-a Cath. This study is therefore based on the hypothesis that Bliss DTx use would : * Be clinically equivalent to a standard protocol (use of hypnotics and/or anxiolytics and/or MEOPA and/or hypnosis conversational) to manage pain during Port-a Cath setting under local anesthesia * Reduce anxiety before setting a Port-a Cath * Provide greater satisfaction with the treatment process from patient point of view * Have organizational impacts, some of which could be economically valued, contributing to optimization of the entire course care for patients with Port-a Cath setting

Interventions

DEVICEPain management with BLISS DTx

Bliss DTx is a Digital Therapeutics (DTx) which uses virtual reality augmented with sound and visual stimuli to reduce pain during Port-A-Cath setting

OTHERPain Management with site standard of care sedation protocol

Sedation (morphine and/or hypnotics and/or anxiolytics and/or conversational hypnosis) reduces pain during Port-A-Cath setting

Sponsors

Butterfly Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient, male or female, aged ≥ 18 years * Patient with a cancer diagnosis * Patient with Port-A-Cath setting under ambulatory * Patient affiliated to or beneficiary of a social security system * French speaking patient having signed informed consent

Exclusion criteria

* Patient with previous Port-A-Cath setting * Patient with pain perception disorder * Patient with contraindication to the use of virtual reality (VR) and screens * Pregnant woman * Protected patient

Design outcomes

Primary

MeasureTime frameDescription
Pain level1 dayMaximum pain level during Port-A-Cath setting will be assessed using Visual Analog Scale : from 0 (no pain) to 10 (intolerable)
Patient anxiety1 dayPatient anxiety before Port-A-Cath setting will be assessed with Hamilton score. Score 10 to 13: mild depressive symptoms. Score 14 to 17: mild to moderate depressive symptoms. Score greater than 18: moderate to severe depressive
Patient satisfaction1 dayThe overall experience score and patient satisfaction will be assessed using the e-Satis questionnaire in ambulatory surgery (MCO CA) at the end of the treatment course. This a specific french questionnaire without global final score. There are only questions with following rating : poor, weak, medium, good, excellent

Countries

France

Contacts

Primary ContactKatell Le Dû, MD
dr.ledu@groupeconfluent.fr+33 2 28 25 56 87

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026